Real World Evaluation of COVID-19 Burden and Nirmatrelvir/Ritonavir in Taiwan Using National Health Insurance Research Database
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 2,315,187
- 试验地点
- 1
- 主要终点
- Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
研究概览
简要总结
The purpose of this study is to learn about:
- effects of living with COVID-19 and
- how effective is nirmatrelvir-ritonavir in treating COVID-19.
This is a study of two groups of COVID-19 patients in Taiwan.
In Group 1 the below participants were included in the study:
- Patients of all ages.
- Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021.
- Cases of patients registered in the databases.
In Group 2 the below participants were included in the study:
- Participants who are 12 years or older.
- Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022.
Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.
The study will look at:
- the nature of Covid-19 disease.
- as well as the experiences of people receiving the nirmatrelvir-ritonavir.
This study will help to:
- understand what type of patients will need to be admitted to hospitals.
- see severe results due to COVID 19 infection.
- have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Patients of all ages
- •Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
- •Cases of patients registered in the databases
排除标准
- •Patients without COVID-19 diagnosis
- •Inclusion Criteria:
- •≥12 years of age
- •Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
- •Exclusion Criteria:
- •Patients without COVID-19 diagnosis
研究组 & 干预措施
Cohort 2 - Cases of patients registered in the databases of ≥12 years of age
Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
干预措施: SoC (Drug)
Cohort 1 - Cases of patients registered in the databases of all ages
Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
干预措施: Disease description (Other)
结局指标
主要结局
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required ICU
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU)
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require ICU
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a diagnosis of COVID-19 that required ICU
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
时间窗: 01 January 2021 to 31 December 2021
Cohort 2: Characteristics Associated with Patients Receiving nirmatrelvir/ritonavir vs Patients Not Receiving nirmatrelvir/ritonavir
时间窗: 01 January 2022 to 31 December 2022
Cohort 1: Comorbidities of Participants with a diagnosis of COVID-19 that did not require ICU
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
时间窗: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
时间窗: 01 January 2021 to 31 December 2021
次要结局
- Cohort 2: Relative Risk for severe COVID-19 By Risk Group(01 January 2022 to 31 December 2022)
- Cohort 2: Incidence for severe COVID-19 Overall(01 January 2022 to 31 December 2022)
- Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Hospital Admission(01 January 2021 to 31 December 2021)
- Cohort 1: Incidence Proportion of ICU Admissions Among COVID-19 Patients Requiring Hospitalization Per Age Range(01 January 2021 to 31 December 2021)
- Cohort 1: Clinical Characteristics Associated to ICU Admission Among Hospitalized COVID-19 Patients(01 January 2021 to 31 December 2021)
- Cohort 1: Mortality Rate Associated to Ventilatory Support Among Hospitalized COVID-19 Patients(01 January 2021 to 31 December 2021)
- Cohort 2: Incidence for severe COVID-19 By Risk Group(01 January 2022 to 31 December 2022)
- Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Required Hospital Admission(01 January 2021 to 31 December 2021)
- Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission(01 January 2021 to 31 December 2021)
- Cohort 2: Relative Risk for severe COVID-19 Overall(01 January 2022 to 31 December 2022)
- Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission(01 January 2021 to 31 December 2021)
- Cohort 1: Clinical Characteristics Associated to Ventilatory Support Among Hospitalized COVID-19 Patients(01 January 2021 to 31 December 2021)
- Cohort 1: Risk Factors Associated to Ventilatory Support Among Hospitalized COVID-19 Patients(01 January 2021 to 31 December 2021)
- Cohort 2: Incidence for severe COVID-19 By Time Period(01 January 2022 to 31 December 2022)
- Cohort 1: Risk Factors Associated to ICU Admission Among Hospitalized COVID-19 Patients(01 January 2021 to 31 December 2021)
- Cohort 1: Average Length of Stay (LOS) of Hospitalized COVID-19 Patients(01 January 2021 to 31 December 2021)
- Cohort 2: Relative Risk for severe COVID-19 By Time Period(01 January 2022 to 31 December 2022)